Navigation Links
Cynosure Reports Second Quarter 2009 Financial Results
Date:7/28/2009

omic uncertainty continues to hinder our domestic revenue performance, we believe we will see an improvement in our U.S. sales once credit loosens and more practitioners are able to obtain financing."

"Despite the challenging environment, we remain unwavering in our commitment to technology and leading the industry through innovation," Davin said. "We continue to invest in our R&D pipeline and have several promising programs underway. In addition, our funded development agreement with Unilever has commenced, and we have taken the first steps toward creating a light-based skin rejuvenation device for the over-the-counter market."

"Although the third quarter traditionally has been the weakest for the aesthetic industry, we are hopeful that the macroeconomic environment will begin to stabilize as we move through the balance of 2009," Davin said. "We continue to carefully manage our business, with the goal to be cash flow neutral for the year. In addition, we are excited about our long-term prospects. We believe we have the global presence, product portfolio, distribution strength and brand reputation to extend our leadership position in the aesthetic industry."

Company Announces Share Repurchase Plan

Cynosure also announced today that its Board of Directors has authorized the repurchase of up to $10 million of the company's common stock from time to time on the open market or in privately negotiated transactions.

"At current levels, we believe the company's stock is attractively valued," Davin said. "This action reflects our ongoing commitment to improving the investment value of our stock while at the same time growing our business."

The timing and amount of any shares repurchased will be determined by the company's management based on its evaluation of market conditions and other factors. Repurchases may also be made under a Rule 10b5-1 p
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Cynosure Announces Presentations at Upcoming Investor Conferences
2. Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting
3. Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy
4. Cynosure Announces Schedule of Upcoming Investor Conferences
5. Cynosure Appoints H. Travis Lee as Vice President of Global Marketing
6. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
7. Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM)
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
11. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... phase transitionsthink solid, liquid, and gasbut much ... drops. If phase transitions occur at the ... subtle fluctuations can dramatically transform a material. ... of Energy,s Brookhaven National Laboratory and Stony ... of absolute zero to isolate and probe ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  FlexTech ... (RFP) for flexible, printed product demonstrators (demos) and ... two-stage RFP process with pre-proposals due on October ... 2015.  Funds for proposals ultimately selected are provided ... have a significant cost share by the proposing ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... Thermo Fisher,Scientific Inc. (NYSE: TMO ) announced ... president and chief executive,officer, are adopting stock- trading ... covering the future sale of company stock. Mr.,Dekkers, ... over August,15-17, 2007, has adopted a plan for ...
... Pharmion - ... - Sirtuins implicated in tumor ... combination epigenetic therapies, BOULDER, Colo. and MONTREAL, Aug. 20 ... MYG) today announced a,research collaboration for the development of novel ...
... CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... second quarter of 2007 increased more than,35% over the ... times,revenues of just $13,351 for the same period in ... of 2007 were $3,256,000 compared to only,$24,374 in the ...
Cached Biology Technology:Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:9/16/2014)... us sick can take up residence in and on ... other troublesome symptom, according to new research at Washington ... On average, healthy individuals carry about five types of ... BioMed Central Biology . The study is the ... in healthy people. , The research was conducted ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... sexy (especially when scientists start analyzing it), but it is ... an egg and a sperm, a whole lot of cell ... that carries a mix of genes from both parents. There ... the most fundamental and important is the transition from unfertilized ...
... new drug has been shown to improve blood flow in ... heart attacks, a Monash University study published today reveals. , ... that, in conjunction with Bayer Health Care, hopes to use ... of heart disease. , Dr. Harald Schmidt, Director of the ...
... men age 40 and older have a significantly increased ... whose fathers are younger than 30 years, according to ... General Psychiatry, one of the JAMA/Archives journals. , Autism ... patterns of behavior, according to background information in the ...
Cached Biology News:Cracking the egg 2Heart smart: new drug improves blood flow 2Older fathers more likely to have autistic children 2
Extra Large bottle for hybridization 300 x 70mm...
CQCS kit for first KR 4i , (first unit)....
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
...
Biology Products: